Compile Data Set for Download or QSAR
Report error Found 45 Enz. Inhib. hit(s) with all data for entry = 10963
TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581318(US11504381, Compound 1 | US11548866, Compound 1)
Affinity DataKd:  9.50E+4nMAssay Description:ITC experiments were run on a Malvern MicroCal Auto-ITC200 or ITC200 machine. Titration experiments were run in 20 mM Phosphate, 150 mM NaCl and 1 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581346(US11504381, Compound 29)
Affinity DataKd:  1.00E+3nMAssay Description:ITC experiments were run on a Malvern MicroCal Auto-ITC200 or ITC200 machine. Titration experiments were run in 20 mM Phosphate, 150 mM NaCl and 1 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581339(US11504381, Compound 22 | US11548866, Compound 22)
Affinity DataKd:  7.60E+4nMAssay Description:ITC experiments were run on a Malvern MicroCal Auto-ITC200 or ITC200 machine. Titration experiments were run in 20 mM Phosphate, 150 mM NaCl and 1 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581338(US11504381, Compound 21 | US11548866, Compound 21)
Affinity DataKd:  400nMAssay Description:ITC experiments were run on a Malvern MicroCal Auto-ITC200 or ITC200 machine. Titration experiments were run in 20 mM Phosphate, 150 mM NaCl and 1 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581336(US11504381, Compound 19 | US11548866, Compound 19)
Affinity DataKd:  2.30E+5nMAssay Description:ITC experiments were run on a Malvern MicroCal Auto-ITC200 or ITC200 machine. Titration experiments were run in 20 mM Phosphate, 150 mM NaCl and 1 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581335(US11504381, Compound 18 | US11548866, Compound 18 ...)
Affinity DataKd:  7.00E+4nMAssay Description:ITC experiments were run on a Malvern MicroCal Auto-ITC200 or ITC200 machine. Titration experiments were run in 20 mM Phosphate, 150 mM NaCl and 1 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581334(US11504381, Compound 17 | US11548866, Compound 17)
Affinity DataKd:  1.50E+4nMAssay Description:ITC experiments were run on a Malvern MicroCal Auto-ITC200 or ITC200 machine. Titration experiments were run in 20 mM Phosphate, 150 mM NaCl and 1 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581332(US11504381, Compound 15 | US11548866, Compound 15)
Affinity DataKd:  7.50E+3nMAssay Description:ITC experiments were run on a Malvern MicroCal Auto-ITC200 or ITC200 machine. Titration experiments were run in 20 mM Phosphate, 150 mM NaCl and 1 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581328(US11504381, Compound 11 | US11548866, Compound 11)
Affinity DataKd:  2.00E+4nMAssay Description:ITC experiments were run on a Malvern MicroCal Auto-ITC200 or ITC200 machine. Titration experiments were run in 20 mM Phosphate, 150 mM NaCl and 1 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581327(US11504381, Compound 10 | US11548866, Compound 10)
Affinity DataKd:  3.20E+4nMAssay Description:ITC experiments were run on a Malvern MicroCal Auto-ITC200 or ITC200 machine. Titration experiments were run in 20 mM Phosphate, 150 mM NaCl and 1 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581324(US11504381, Compound 7 | US11548866, Compound 7)
Affinity DataKd:  1.80E+4nMAssay Description:ITC experiments were run on a Malvern MicroCal Auto-ITC200 or ITC200 machine. Titration experiments were run in 20 mM Phosphate, 150 mM NaCl and 1 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581323(US11504381, Compound 6 | US11548866, Compound 6)
Affinity DataKd:  3.40E+4nMAssay Description:ITC experiments were run on a Malvern MicroCal Auto-ITC200 or ITC200 machine. Titration experiments were run in 20 mM Phosphate, 150 mM NaCl and 1 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581320(US11504381, Compound 3 | US11548866, Compound 3)
Affinity DataKd:  2.20E+4nMAssay Description:ITC experiments were run on a Malvern MicroCal Auto-ITC200 or ITC200 machine. Titration experiments were run in 20 mM Phosphate, 150 mM NaCl and 1 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581322(US11504381, Compound 5)
Affinity DataKd:  2.40E+4nMAssay Description:ITC experiments were run on a Malvern MicroCal Auto-ITC200 or ITC200 machine. Titration experiments were run in 20 mM Phosphate, 150 mM NaCl and 1 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581348(US11504381, Compound 31 | US11548866, Compound 31)
Affinity DataKi:  300nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581346(US11504381, Compound 29)
Affinity DataKi:  500nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581347(US11504381, Compound 30 | US11548866, Compound 30)
Affinity DataKi:  800nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581338(US11504381, Compound 21 | US11548866, Compound 21)
Affinity DataKi:  1.50E+3nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581333(US11504381, Compound 16 | US11548866, Compound 16)
Affinity DataKi:  4.00E+3nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581337(US11504381, Compound 20 | US11548866, Compound 20)
Affinity DataKi:  6.00E+3nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581332(US11504381, Compound 15 | US11548866, Compound 15)
Affinity DataKi:  9.00E+3nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581325(US11504381, Compound 8 | US11548866, Compound 8)
Affinity DataKi:  1.10E+4nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581330(US11504381, Compound 13 | US11548866, Compound 13)
Affinity DataKi:  1.30E+4nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581328(US11504381, Compound 11 | US11548866, Compound 11)
Affinity DataKi:  1.60E+4nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581324(US11504381, Compound 7 | US11548866, Compound 7)
Affinity DataKi:  1.80E+4nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581343(US11504381, Compound 26 | US11548866, Compound 26)
Affinity DataKi:  2.20E+4nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581331(US11504381, Compound 14 | US11548866, Compound 14)
Affinity DataKi:  2.30E+4nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581322(US11504381, Compound 5)
Affinity DataKi:  2.80E+4nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581320(US11504381, Compound 3 | US11548866, Compound 3)
Affinity DataKi:  2.90E+4nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581335(US11504381, Compound 18 | US11548866, Compound 18 ...)
Affinity DataKi:  3.40E+4nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581344(US11504381, Compound 27 | US11548866, Compound 27)
Affinity DataKi:  3.60E+4nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581327(US11504381, Compound 10 | US11548866, Compound 10)
Affinity DataKi:  3.90E+4nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581345(US11504381, Compound 28 | US11548866, Compound 28)
Affinity DataKi:  4.60E+4nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581334(US11504381, Compound 17 | US11548866, Compound 17)
Affinity DataKi:  6.00E+4nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581339(US11504381, Compound 22 | US11548866, Compound 22)
Affinity DataKi:  6.10E+4nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581342(US11504381, Compound 25 | US11548866, Compound 25)
Affinity DataKi:  6.10E+4nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581323(US11504381, Compound 6 | US11548866, Compound 6)
Affinity DataKi:  6.80E+4nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581340(US11504381, Compound 23 | US11548866, Compound 23)
Affinity DataKi:  7.50E+4nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581318(US11504381, Compound 1 | US11548866, Compound 1)
Affinity DataKi:  9.20E+4nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581335(US11504381, Compound 18 | US11548866, Compound 18 ...)
Affinity DataKi:  1.06E+5nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581321(US11504381, Compound 4 | US11548866, Compound 4)
Affinity DataKi:  1.07E+5nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581319(US11504381, Compound 2 | US11548866, Compound 2)
Affinity DataKi:  1.18E+5nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581336(US11504381, Compound 19 | US11548866, Compound 19)
Affinity DataKi:  1.40E+5nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581329(US11504381, Compound 12 | US11548866, Compound 12)
Affinity DataKi: >2.50E+5nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2(Human)
Ligature Therapeutics

US Patent
LigandPNGBDBM581326(US11504381, Compound 9 | US11548866, Compound 9)
Affinity DataKi: >2.50E+5nMAssay Description:The compounds binding to MDM2 were determined by a quantitative fluorescence polarization binding assay using a recombinant MDM2 protein and fluoresc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2023
Entry Details
Go to US Patent